Orchestra Biomed Holding Banner Image

Orchestra Biomed Holding

  • Ticker OBIO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Orchestra Biomed Holding Logo Image
  • 1-10 Employees
  • Based in New Hope, Pennsylvania
Orchestra BioMed is a biomedical innovation company focused on developing transformative therapeutic products for large unmet needs in procedure-based medicine. The Company is led by a highly accomplished, multidisciplinary management team and board of directors with extensive experience in all phases of medical device development. Orchestra BioMed’s partnership-enabled business model focusesMore on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed was formed in 2018 by assembling a pipeline of multiple late-stage clinical product candidates originally developed by the Company’s founding team. The Company’s flagship product candidates are Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of artery disease, the leading cause of mortality, and BackBeat Cardiac Neuromodulation Therapy™ for the treatment of hypertension, the leading risk factor for death worldwide. Orchestra BioMed has a global strategic partnership with Terumo Corporation, one of the world’s largest medical device companies, for development and commercialization of Virtue SAB. The Company has additional product candidates in its pipeline and plans to thoughtfully expand its product pipeline in the future through acquisitions, strategic collaborations, licensing, and organic development.
Orchestra Biomed Holding

Most Recent Annual Report

Orchestra Biomed Holding
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Orchestra Biomed Holding Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!